Use of Somatostatin Analogues in Obesity
Authors:
- Themistoklis TzotzasTTThemistoklis Tzotzas
- Petros PerrosPPPetros Perros
- Gerasimos E KrassasGKGerasimos E Krassas
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 68 (14) , 1963-1973
Abstract
Obesity is a condition that results from dysregulation of energy balance. Insulin, a component of the efferent pathway of the energy-regulatory circuit, promotes storage of energy substrates in adipose tissue and is, therefore, a potential target for pharmacotherapy. Somatostatin and its analogues (octreotide and lanreotide) bind to somatostatin subtype 5 receptors on the β-cell membrane, which limits insulin release and, consequently, may decrease adipogenesis. Somatostatin and its analogues have been used in trials in patients with paediatric hypothalamic obesity. These children have hypothalamic dysfunction, mainly due to brain tumours such as craniopharyngiomas, which are thought to generate increased vagal output, leading to hyperinsulinaemia and weight gain. Two small trials, each of 6 months’ duration, in children with paediatric hypothalamic obesity showed either a minimal weight loss or stabilization of bodyweight. In children with Prader-Willi syndrome, the most common genetic hypothalamic disorder associated with hyperphagia, hyperghrelinaemia, massive obesity and other endocrine disturbances, somatostatin failed to control hyperphagia and weight gain in a small number of patients, although it lowered the levels of the anorexigenic hormone ghrelin. Long-acting release octreotide was recently used in hyperinsulinaemic obese adults without cranial pathology. Insulin suppression was associated with small decreases in the body mass indexes of obese subjects receiving the higher dosages of the drug, with an acceptable safety profile, similar to that in previous studies. In conclusion, somatostatin and its analogues, by suppressing β-cell insulin secretion, can retard weight gain in children with hypothalamic obesity and induce a small amount of weight loss in some adults with hyperinsulinaemic obesity.Keywords
This publication has 81 references indexed in Scilit:
- Neural Mechanisms Underlying Hyperphagia in Prader‐Willi SyndromeObesity, 2006
- Weight Gain in Craniopharyngioma - A Model for Hypothalamic ObesityJournal of Pediatric Endocrinology and Metabolism, 2006
- Insulin Dynamics Predict Body Mass Index and Z-Score Response to Insulin Suppression or Sensitization Pharmacotherapy in Obese ChildrenThe Journal of Pediatrics, 2006
- Racial and etiopathologic dichotomies in insulin hypersecretion and resistance in obese childrenThe Journal of Pediatrics, 2005
- Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatmentClinical Endocrinology, 2003
- Octreotide Long-Acting Release (LAR)Drugs, 1997
- Insulin Normalization as an Approach to the Pharmacological Treatment of ObesityObesity Research, 1995
- TRUNCAL VAGOTOMY IN HYPOTHALAMIC OBESITYThe Lancet, 1983
- The role of vagally-mediated hyperinsulinemia in hypothalamic obesityNeuroscience & Biobehavioral Reviews, 1982
- An autonomic hypothesis for hypothalamic obesityLife Sciences, 1979